Early pancreas transplant outcomes with histidine-tryptophan-ketoglutarate preservation: a multicenter study

• Published in: Transplantation Vol. 82; no. 1; p. 136
• Main Authors: Englesbe, Michael J, Moyer, Alice, Kim, Dean Y, Granger, Darla K, Pietroski, Richard, Yoshida, Atsushi, Arenas, Juan D, Oh, Henry, Pelletier, Shawn J, Campbell, Jr, Darrell A, Punch, Jeffrey D, Magee, John C, Gruber, Scott A, Sung, Randall S
• Format: Journal Article
• Language: English
• Published: United States 15.07.2006
• Subjects: Adult; Female; Glucose - pharmacology; Graft Rejection; Graft Survival; Humans; Male; Mannitol - pharmacology; Organ Preservation Solutions - pharmacology; Pancreas - drug effects; Pancreas Transplantation; Potassium Chloride - pharmacology; Procaine - pharmacology
• DOI: 10.1097/01.tp.0000225764.21343.e3
• ISSN: 0041-1337

Little is known about the use of histidine-tryptophan-ketoglutarate (HTK) preservation solution for pancreas preservation. We compared early pancreas graft outcomes at four pancreas transplant programs within the state of Michigan in 2002 and 2003 (University of Wisconsin [UW] era) with those in 2004 (HTK era). The primary endpoint was early graft loss. The UW group (n=41) and the HTK group (n=36) had similar outcomes with respect to: technical graft loss (9.8% vs. 8.3%, P=NS), 90-day graft function (90.2% vs. 86.1%, P=NS), and rate of pancreatic leak/abscess (12.2% vs. 11.1%, P=NS). There were also no significant differences in postoperative amylase and lipase levels between the two groups. The HTK group did have significantly more acute rejection within the first 180 days (25.0% vs. 9.8%, P<0.05). HTK is a suitable substitute for UW in the preservation of pancreas allografts.